Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis

Table 1 Methodological characteristics of the included studies in this meta-analysis

Ref.	Methodological quality	Sample size	Intervention	Control	Duration	Follow-up
Lee et al[23]	RCT	20 (11/9)	Pentoxifylline (1200 mg/d) plus low-calorie diet and exercise	Placebo plus low-calorie diet and daily exercise	12 wk	Yes
Tuncer et al[24]	Prospective cohort study with concurrent control	20 (10/10)	Pentoxifylline (20 mg/kg per day)	UDCA	24 wk	Yes
Georgescu et al[25]	Prospective cohort study with concurrent control	26 (13/13)	Pentoxifylline (800 mg/d)	UDCA	30 wk	Yes
Zein et al[26]	RCT	55 (26/29)	Pentoxifylline (1200 mg/d)	Placebo	12 mo	Yes
Van Wagner et al[27]	RCT	26 (19/7)	Pentoxifylline (1200 mg/d)	Placebo	12 mo	Yes

RCT: Randomized controlled trial; UDCA: Ursodeoxycholic acid.